Clinical TrialMay 20, 2026, 08:46 AM
Propanc Biopharma Plans Phase 1b Clinical Trial for PRP
AI Summary
Propanc Biopharma, Inc. announced its intention to file a Clinical Trial Application (CTA) in Australia later this year for a Phase 1b, First-In-Human study of its lead asset, PRP. This study will involve 30-40 advanced cancer patients with solid tumors, utilizing an intravenous formulation of PRP administered once weekly. Following the completion of Phase 1, the company plans to conduct two Phase 2 studies, each with 60 patients, targeting pancreatic and ovarian cancers. The CEO also highlighted broader advancements in pancreatic cancer treatment, reinforcing the company's focus on biologically informed strategies.
Key Highlights
- Propanc Biopharma plans to file a Clinical Trial Application (CTA) in Australia later this year.
- The CTA is for a Phase 1b, First-In-Human study of its lead asset, PRP, in an IV formulation.
- The Phase 1b study will enroll 30-40 advanced cancer patients suffering from solid tumors.
- PRP will be administered once weekly at significantly higher doses than previous compassionate use.
- Following Phase 1, the company plans two Phase 2 studies, each with 60 patients.
- Phase 2 studies will target pancreatic and ovarian cancers to establish proof of concept.
- PRP received USFDA Orphan Drug Designation for pancreatic cancer in 2017.
- Compassionate use data showed 3 out of 4 patients significantly exceeding life expectancy.
Price Impact
More from PPCB